HCW Biologics(US:HCWB)2026-03-31 21:12Revenue Performance - Revenues for Q4 2025 were $27,010, a significant decrease from $394,804 in Q4 2024, and annual revenues dropped from $2.6 million in 2024 to $54,232 in 2025[11] - Revenues for the three months ended December 31, 2024, were $394.8 million, a significant increase compared to $27.0 million for the same period in 2025[23] - Net revenues for the year ended December 31, 2024, reached $959.4 million, up from $10.8 million in 2025, indicating strong growth[23] Expenses - R&D expenses increased by 27% in Q4 2025 to $1.3 million compared to $1.0 million in Q4 2024, while annual R&D expenses decreased by 15% from $6.4 million in 2024 to $5.4 million in 2025[12] - G&A expenses for Q4 2025 were $1.5 million, down 26% from $2.0 million in Q4 2024, but increased by 13% for the year from $6.8 million in 2024 to $7.7 million in 2025[13] - Total operating expenses for the three months ended December 31, 2024, were $3.24 billion, compared to $4.47 billion in 2025, reflecting a decrease in expenses[23] Net Income/Loss - The net gain for Q4 2025 was $2.2 million, a turnaround from a net loss of $3.4 million in Q4 2024; however, the annual net loss decreased from $30.0 million in 2024 to $6.5 million in 2025[15] - The net loss for the three months ended December 31, 2024, was $3.37 billion, compared to a net profit of $719.2 million in 2025[23] - The company reported a net loss per share of $3.19 for the three months ended December 31, 2024, compared to a loss of $1.02 in 2025[23] Financial Position - Cash and cash equivalents as of December 31, 2024, were $4.67 million, down from $1.95 million in 2025, indicating a decrease in liquidity[25] - Total assets decreased from $30.24 million in 2024 to $24.52 million in 2025, showing a decline in overall asset value[25] - Total liabilities increased significantly from $37.01 million in 2024 to $21.76 million in 2025, indicating a shift in financial obligations[25] - The accumulated deficit grew from $100.56 million in 2024 to $108.52 million in 2025, reflecting ongoing financial challenges[25] Business Development - The company received a $3.5 million upfront licensing fee for HCW11-006, with $2.9 million net after taxes, and is eligible for additional milestone payments and royalties[7] - HCW9302, the lead product candidate, is currently in a Phase 1 clinical trial for alopecia areata, with preliminary human data expected in the first half of 2026[5] - The company launched two proprietary fusion protein molecules as commercial-ready reagents to support the production of cell-based immunotherapeutics during 2025[9] - HCW Biologics is focusing on business development programs and has entered into two licensing agreements for its proprietary molecules[19] Compliance and Concerns - The Nasdaq Hearings Panel confirmed the company regained compliance with listing rules, but it faces ongoing scrutiny regarding its stock price following a reverse stock split[17] - The company has substantial doubt about its ability to continue as a going concern for at least 12 months without additional funding[16] Shareholder Impact - The weighted average shares outstanding increased from 1,057,542 in 2024 to 3,384,062 in 2025, indicating potential dilution of shares[23]